Pari Pharma GmbH
5 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis (NCT01955980) | Pari Pharma GmbH | 2015-10-27 |
| Bioequivalence and Safety of Vantobra and TOBI in Healthy Subjects (NCT01953367) | Pari Pharma GmbH | 2013-09-01 |
| Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi (NCT01946711) | Pari Pharma GmbH | 2013-08-28 |
| Long-term Safety Follow-up Study in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) (NCT01439958) | Pari Pharma GmbH | 2012-02-01 |
| L-CsA in the Prevention of Bronchiolitis Obliterans Syndrome (BOS) in Lung Transplant (LT) Patients (NCT01334892) | Pari Pharma GmbH | 2009-12-01 |
Track Pari Pharma GmbH automatically
Every clearance here is in the API, with alerts when new ones post.